Our results showed that previous multi-drug and long-term chemotherapy treatment has clear efficacy, and our recent studies indicate that immunomodulatory treatment as pre-chemotherapy therapy can also benefit patients and improved HAVCR2 mutation testing to identify patients requiring intensive treatment for HPS. The gene discussed is HAVCR2; the disease is Hermansky-Pudlak syndrome.